{
    "nctId": "NCT00733408",
    "briefTitle": "Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer",
    "officialTitle": "Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib",
    "overallStatus": "COMPLETED",
    "conditions": "Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 59,
    "primaryOutcomeMeasure": "Progression-free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have histologically confirmed invasive breast cancer that is estrogen receptor (ER) negative (=\\< 10%), progesterone receptor (PR) negative (=\\< 10%) and human epidermal growth factor receptor 2 (HER2) normal (=\\< 10% of cells) by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)\n* Be receiving first-line therapy for metastatic disease\n* Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration\n* OR non-measurable disease only, with rising serum cancer antigen (CA)15-3 or CA 27.29 or carcinoembryonic antigen (CEA) documented by two consecutive measurements taken at least 14 days apart with the most recent measurement being within 42 days prior to registration; the second CA 15-3 or CA 27.29 or CEA value must have at least a 20% increase over the first and for CA 15-3 or CA 27.29 be greater than or equal to 40 units/mL or for CEA be greater than or equal to 4 ng/mL\n* Subjects with brain metastases as their first site of disease recurrence may be eligible if treated by definitive radiation (stereotactic radiosurgery or whole brain) with clinically controlled neurologic symptoms for a period of 21 days prior to study treatment\n* Bilirubin =\\< 1.5 mg/dL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis\n* Alkaline phosphatase =\\< 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis\n* Platelets \\> 100,000 cells/mm\\^3\n* Hemoglobin \\> 9.0 g/dL\n* Absolute neutrophil count (ANC) \\>= 1,500 cells/mm\\^3\n* Creatinine =\\< 1.5 mg/dL is recommended; however, institutional norms are acceptable\n* If of childbearing potential must have a negative pregnancy test and use an effective method to avoid pregnancy for the duration of the trial and for at least 6 months after completion of study therapy\n* Pre-existing peripheral neuropathy, if present, must be \\< grade 2 (per Common Terminology Criteria for Adverse Events \\[CTCAE\\] version 3.0)\n* Patients must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional standards and federal guidelines\n\nExclusion Criteria:\n\n* Recurrent disease within 12 months after completion of adjuvant chemotherapy containing a weekly taxane\n* Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids\n* Pre-existing nephritic syndrome\n* Serious intercurrent medical or psychiatric illness including serious active infection\n* Inadequately controlled hypertension (defined as systolic blood pressure \\> 150 and/or diastolic blood pressure \\> 100 mmHg on antihypertensive medications)\n* Any prior history of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association (NYHA) grade II or greater congestive heart failure\n* History of myocardial infarction or unstable angina within 6 months prior to study enrollment\n* History of stroke or transient ischemic attack within 6 months prior to study enrollment\n* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)\n* Symptomatic peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study\n* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment\n* Serious, non-healing wound, ulcer, or bone fracture\n* Proteinuria at screening as demonstrated by either:\n\n  * Urine protein:creatinine (UPC) ratio \\>= 1.0 at screening OR\n  * Urine dipstick for proteinuria \\> 2+ (patients discovered to have \\> 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is \\< 1.0 to be eligible; if the UPC ratio is \\>= 1.0 then the patient should undergo a 24-hour urine collection which must demonstrate =\\< 1 g of protein in 24 hours for the patient to be eligible)\n* Known hypersensitivity to any component of bevacizumab or to nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}